David Shprecher is a Neurology physician affiliated with Banner Sun Health Research Institute. OpenAlex indexes 133 publications with 4,120 citations (h-index 33); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10515 W Santa Fe Dr Bldg B
Sun City, AZ 853513020
Telephone
623-832-6530Provider last certified this registry record 4 Sept 2024.
Clinical trials
- MRI Study of Tic Remission in Tourette Syndrome
Sponsor: University of Utah
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
28 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20256 payments
- Medtronic, Inc.Program year20254 payments
- Teva Pharmaceuticals USA, Inc.Program year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
75.3%Neuromuscular Blocker75.1%Onabotulinumtoxina100%Part B, office-administered≥21 patientsgamma-Aminobutyric Acid-ergic Agonist0.1%Baclofen100%Part D<11 patients+ 1 more class in this area
Nervous system
22.4%Aromatic Amino Acid Decarboxylation Inhibitor6.9%Carbidopa-Levodopa51%Carbidopa-Levodopa Er24%Rytary23%Crexont2%Part D<11 patientsNonergot Dopamine Agonist2%Pramipexole Dihydrochloride73%Ropinirole Hcl16%Ropinirole Er6%Pramipexole Er5%Part D<11 patients+ 20 more classes in this area
Cardiovascular
1.7%Beta blocker1%Propranolol Hcl Er47%Propranolol Hcl35%Atenolol18%Part D<11 patientsAdrenergic and dopaminergic agents0.6%Droxidopa100%Part D≥11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study over 12 months
npj Parkinson s Disease
2024 - Consensus practice recommendations for management of gastrointestinal dysfunction in Parkinson disease
Parkinsonism & Related Disorders
2024 - Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study
npj Parkinson s Disease
2023 - Baseline characteristics of the North American prodromal Synucleinopathy cohort
Annals of Clinical and Translational Neurology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”